Trials / Completed
CompletedNCT00163488
Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)
Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Fluticasone Propionate/Salmeterol (FP/SAL) in Patients (18-60 Years) With Perennial Allergic Rhinitis (PAR)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 106 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of combined ciclesonide nasal spray administered along with a fixed combination of inhaled fluticasone dipropionate/salmeterol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ciclesonide |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2005-08-01
- Completion
- 2005-08-01
- First posted
- 2005-09-14
- Last updated
- 2016-12-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00163488. Inclusion in this directory is not an endorsement.